• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Machine renal perfusion reduces delayed graft function after transplantation

byBryant LimandKiera Liblik
February 8, 2023
in Chronic Disease, Nephrology
Reading Time: 2 mins read
State policies for organ donation may be largely ineffective
Share on FacebookShare on Twitter

1. In this randomized controlled trial, machine perfusion of the kidney reduced delayed graft function compared to therapeutic hypothermia. 

2. There were no significant differences in one-year graft survival frequency between groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Therapeutic hypothermia and machine organ perfusion reduce the risk of delayed graft function in kidney transplant recipients. However, machine perfusion is complex and involves high costs for transplant centers. There is a paucity of evidence comparing transplant outcomes between organ preservation methods. This randomized controlled trial evaluated whether donor hypothermia (34˚C to 35˚C) is noninferior to machine perfusion and whether combination therapy is superior to individual therapy to reduce the risk of delayed graft function in transplant recipients. Graft survival one year after transplantation was also evaluated. The study was prematurely terminated due to the futility of showing the superiority of combination therapy compared to individual therapies. For delayed graft function, hypothermia alone was inferior to machine perfusion, while combination therapy was not superior to machine perfusion. There were no significant differences in kidney graft survival at one year. As a limitation, the study was not blinded and there were changes in patient randomization and an early study termination due to futility.

Click to read the study in NEJM

Relevant Reading: Therapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function

RELATED REPORTS

Perioperative vitamin C supplementation may not reduce bleeding in percutaneous renal biopsy patients

An intradialytic exercise intervention did not improve dialysis adequacy

Point-of-care ultrasound may be effective at identifying nephrolithiasis in the emergency department

In-Depth [randomized controlled trial]: In this randomized controlled clinical trial, therapeutic hypothermia, machine perfusion, and combined therapy were compared in terms of delayed graft function and graft survival for kidney transplantations. The target temperature for mild hypothermia was 34˚C to 35˚C. A total of 1,349 kidneys were obtained from 725 donors. Eligible brain-dead donors who were at least 18 years old with research authorization were randomized in a 1:1:1 ratio to hypothermia alone (n=359), machine perfusion alone (n=511), or a combination of both methods (n=479). The trial was terminated early for futility in showing the superiority of combination therapy over machine perfusion alone. For the primary outcome, delayed graft function occurred in 30%, 19%, and 22% of the hypothermia alone, machine-perfusion alone, and combination therapy groups, respectively. The model-adjusted odds ratio was 2.21 (95% Confidence Interval [CI], 1.57 to 3.1) for hypothermia alone compared to machine perfusion alone and 1.93 (95% CI, 1.39 to 2.69) for hypothermia compared to combination therapy. There were no significant differences between machine perfusion alone and combination therapy for delayed graft function. For the secondary outcome, there were no significant differences in one-year kidney graft survival between the three groups. This study shows that machine perfusion of kidneys from brain-dead donors was superior to hypothermia treatment alone in delayed graft function. Combination therapy did not improve outcomes over machine perfusion alone.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chronic diseasedelayed graft function after transplantationkidney transplantmachine perfusionnephrologyorgan transplantrenal transplanttherapeutic hypothermiatransplant medicine
Previous Post

COVID-19 mRNA vaccines are safe and effective in children aged 5 to 11 years

Next Post

Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis

RelatedReports

Blood type correlates with egg reserve in infertile women
Nephrology

Perioperative vitamin C supplementation may not reduce bleeding in percutaneous renal biopsy patients

July 10, 2026
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Chronic Disease

An intradialytic exercise intervention did not improve dialysis adequacy

May 18, 2026
Renal stones in women linked with increased risk of coronary heart disease
Emergency

Point-of-care ultrasound may be effective at identifying nephrolithiasis in the emergency department

May 11, 2026
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Nephrology

Sparsentan (Filspari) becomes first approved treatment for focal segmental glomerulosclerosis

May 6, 2026
Next Post
JAK2 and TET2 mutations temporally linked with myeloproliferative disorder outcomes

Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis

Palliative care consultation linked to lower deaths by failed code resuscitation

Wellness Check: Spirituality

UTI associated with increased risk of preeclampsia

Baxdrostat reduces blood pressure in previously treatment-resistant hypertension

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Azacitidine–venetoclax improved event-free survival in induction-eligible AML
  • Bundibugyo Ebola outbreak surpasses 5,700 cases without a validated vaccine
  • Cognitive behaviour therapy may be superior to bright light therapy for insomnia in women with breast cancer undergoing chemotherapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.

2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in